NASDAQ: PRPOPrecipio Inc Stock
$6.08+0.33 (+5.74%)
Updated Apr 30, 2025
PRPO Price
$6.08
Fair Value Price
N/A
Market Cap
$9.15M
52 Week Low
$3.90
52 Week High
$10.74
P/E
-2.08x
P/B
0.76x
P/S
0.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.53M
Earnings
-$4.29M
Gross Margin
40.8%
Operating Margin
-22.75%
Profit Margin
-23.1%
Debt to Equity
0.41
Operating Cash Flow
$439k
Beta
0.61
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PRPO Overview
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PRPO's potential to beat the market
- PRPO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
PRPO
RankedUnranked of 44
RankedUnranked of 44
Be the first to know about important PRPO news, forecast changes, insider trades & much more!
PRPO News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRPO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRPO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRPO is good value based on its book value relative to its share price (0.76x), compared to the US Diagnostics & Research industry average (3.39x)
P/B vs Industry Valuation
PRPO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PRPO due diligence checks available for Premium users.
Valuation
PRPO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.08x
Industry
39.05x
Market
29.18x
PRPO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.76x
Industry
3.39x
PRPO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRPO's financial health
Profit margin
Revenue
$5.5M
Net Income
-$365.0k
Profit Margin
-6.7%
PRPO's Earnings (EBIT) of -$4.22M... subscribe to Premium to read more.
Interest Coverage Financials
PRPO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$17.0M
Liabilities
$4.9M
Debt to equity
0.41
PRPO's short-term liabilities ($4.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRPO's short-term assets ($3.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRPO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PRPO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$565.0k
Investing
-$44.0k
Financing
-$185.0k
PRPO's operating cash flow ($439.00k)... subscribe to Premium to read more.
Debt Coverage Financials
PRPO vs Diagnostic & Research Stocks
Precipio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.